Introduction {#S1}
============

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common dominantly-inherited muscular dystrophies, with prevalence frequencies ranging from 1:15,000 to 1:21,000 worldwide ([@B9]). Classically, FSHD manifests in progressive, often asymmetrical muscular weakness, most prominently in the face, shoulder girdle, and upper-arm region ([@B35]; [@B38]). Unlike in other forms of muscular dystrophy, in which the presence of cardiomyopathy and pulmonary impairment frequently results in a heightened mortality rate ([@B25]), life expectancy among individuals with FSHD appears to be preserved ([@B35]). However, impairments in functional capacity, as measured by a decreased capacity for independent ambulation ([@B38]), and a greater reliance on assistive devices among older adults with FSHD (\>50 years), have been reported in this population ([@B34]). It is speculated that this functional impairment may be partially driven by alterations in body composition, which likewise have been linked to high rates of skeletal muscle atrophy ([@B35]; [@B38]) and corresponding increases in fatty tissue infiltration of the muscular compartments ([@B20]). For example, [@B20] demonstrated that up to 26% of individuals with FSHD may experience severe rates of fatty infiltration, whereby as much as 75% of lean tissue in certain muscular compartments is replaced by fat mass, an observation that may have clinical and functional implications for people with FSHD.

With the manifestation of muscular atrophy and increased proportion of fat mass, it is likely that people with FSHD exhibit a medical condition known as sarcopenic obesity. Sarcopenic obesity combines the key features of sarcopenia \[losses in muscle mass, declining strength, and/or impairments in physical performance ([@B8])\] with an increased presence of adiposity ([@B30]). Adults who meet diagnostic criteria for sarcopenic obesity have been reported to exhibit an increased risk of mortality (hazard ratio: 1.44) as compared to control counterparts ([@B2]), and show a greater propensity toward physical disability ([@B3]). It is believed that sarcopenic obesity contributes to physical disability via a combination of concurrent changes, including the loss and atrophy of type II muscle fibers ([@B37]) and a greater propensity toward fatty infiltration of skeletal muscle ([@B14]). These skeletal muscle alterations lead to impairments in the contractile strength of type I and II muscle fibers ([@B17]), and overall reductions in muscular power.

While sarcopenic obesity has been noted among individuals with various types of muscular dystrophy \[i.e., Duchenne, Becker, and Ullrich congenital muscular dystrophies ([@B26])\], it is unclear if people with FSHD exhibit this condition. By identifying sarcopenic obesity as a potential comorbidity of FSHD, the development of effective preventative and therapeutic strategies designed to address the condition may be incorporated as part of the medical treatment plan, thereby leading to gains in functional capacity, a greater ability to perform activities of daily living (ADLs), and an overall improvement in quality of life. Therefore, we aimed to determine if people with FSHD meet the diagnostic criteria for sarcopenic obesity. We hypothesized that the anatomic characteristics associated with the presence of sarcopenic obesity are more pronounced among people with FSHD, as compared to age- and sex-matched controls.

Materials and Methods {#S2}
=====================

Subjects {#S2.SS1}
--------

Ten adults with genetically-confirmed FSHD and ten age- and sex-matched healthy control participants (*n* = 20 combined; men: 16, women: 4) completed the study. Inclusion criteria consisted of an age of ≥ 18 years, and no prior history of cardiovascular, pulmonary, orthopedic, or neuromuscular disorders other than FSHD; female participants were excluded if they were currently pregnant or breastfeeding ([@B10]; [@B24]). Physical activity levels were assessed via the Modified Minnesota Leisure Time Physical Activity Questionnaire, and reported as an activity metabolic index score ([@B31]). Severity of disease burden among individuals with FSHD was evaluated through completion of the FSHD Health Index survey, whereby a score of 100 reflects the highest disease, and 0 reflects no disease burden ([@B21]; [@B16]). The study was approved by the University of Minnesota Institutional Review Board, and conducted in accordance with the Declaration of Helsinki.

Experimental Protocol {#S2.SS2}
---------------------

Study participants attended one study session, which included a written informed consent following a description of the study design and a total-body dual-energy x-ray absorptiometry (DXA) scan (Lunar iDXA, GE Healthcare, Chicago, IL, United States); female participants took a urine human chorionic gonadotropin (hCG) test (Clinical Guard, Atlanta, GA, United States) to confirm the absence of pregnancy.

Data Collection Techniques {#S2.SS3}
--------------------------

Body composition was obtained from the DXA scan; an estimation of regional and whole body total mass \[kilograms (kg)\], fat mass \[FM (kg, %)\], lean mass \[LM (kg, %)\], and bone mineral content (g) was provided by enCORE v16 (GE Healthcare, Chicago, IL, United States). As FSHD is primarily a disease that affects the upper extremity, differences between upper and lower lean and fat mass were also obtained. Appendicular lean mass (ALM) was quantified as the sum of fat- and bone-free tissue in the arms and legs, and was normalized to height to control for fluctuations in body size ([@B26]). An appendicular lean mass index \[ALMI; ALM weight (kilograms (kg)\]/height^2^ \[meters (m), m^2^)\] was utilized as an index of sarcopenia ([@B26]), whereby the presence of sarcopenia was defined by an ALMI that is two standard-deviations lower than ALMI from the means observed in sex-specific reference groups ([@B5]). Sarcopenic obesity was defined by the combined presentation of an ALMI of \< 7.26 kg/m^2^ and proportion of whole body FM to whole body total mass (% FM) of \> 28%, or an ALMI of \< 5.45 kg/m^2^ and % FM of \> 40%, in men and women, respectively ([@B5]). Body mass index (BMI) was calculated from manual measurements of height (m) and weight (kg); study participants were categorized by BMI status into standard body composition categories ([@B39]).

Statistical Analysis {#S2.SS4}
--------------------

Data is reported as group averages (mean ± standard deviation), distribution normality was assessed and parametric vs. non-parametric methods were used as appropriate. Independent samples *t*-tests were used to compare differences in body composition between FSHD and control participants; in cases where the data was not normally distributed, the Mann-Whitney *U*-test was performed. Pearson product moment correlation was used to determine relationships between continuous variables. Statistical analyses were performed using SPSS v24.0 (SPSS, Inc., Chicago, IL, United States) with significance defined as an α-level of *p* \< 0.05 for all comparisons.

Results {#S3}
=======

Subject Characteristics {#S3.SS1}
-----------------------

FSHD and control participants were similar in age, weight, height, and BMI (*p* \> 0.05 for all, [Table 1](#T1){ref-type="table"}). In the FSHD group, all 10 participants self-reported as non-Hispanic (NH) White; among controls, self-reported race was as follows: NH White: 7 (5 men, 2 women), Black: 1, Asian: 1, Hispanic: 1. Overall, the whole body total mass \[calculated as sum of whole body fat mass (kg), whole body lean mass (kg), and bone mineral content (kg)\] of individuals with FSHD was similar to that of healthy controls (84.5 ± 12.9 vs. 81.8 ± 13.5 kg, respectively, *p* = 0.65, [Table 2](#T2){ref-type="table"}).

###### 

Subject characteristics.

                               FSHD          Range (FSHD)   Control       Range (control)   *p*-value
  ---------------------------- ------------- -------------- ------------- ----------------- -----------
  **Age (years)**                                                                           
  Males and females combined   50 ± 11       36--72         47 ± 13       31--75            0.60
  Males                        51 ± 12       36--72         48 ± 14       31--75            0.68
  Females                      45 ± 9        38--51         41 ± 14       31--51            0.80
  **Weight (kg)**                                                                           
  Males and females combined   85.4 ± 12.9   65.5--105.7    81.8 ± 13.4   65.3--103.7       0.55
  Males                        86.8 ± 12.0   67.9--105.7    81.6 ± 15.1   65.3--103.7       0.46
  Females                      79.8 ± 20.1   65.5--94.0     82.7 ± 4.5    79.5--85.9        0.87
  **Height (m)**                                                                            
  Males and females combined   1.80 ± 0.07   1.67--1.91     1.74 ± 0.08   1.63--1.78        0.09
  Males                        1.84 ± 0.04   1.78--1.91     1.76 ± 0.09   1.68--1.87        0.06
  Females                      1.70 ± 0.04   167--1.73      1.70 ± 0.10   1.63--1.78        0.95
  **BMI (kg/m^2^)**                                                                         
  Males and females combined   26.1 ± 4.4    21.4--33.7     26.7 ± 3.6    21.5--32.2        0.77
  Males                        25.7 ± 3.7    21.4--29.9     26.2 ± 3.4    21.5--31.8        0.80
  Females                      27.8 ± 8.3    21.9--33.7     28.7 ± 5.0    25.1--32.2        0.92

Individuals with FSHD and controls were similar in age, height, weight and body mass index (BMI). kg: kilograms; m: meters; data are presented in mean ± SD.

###### 

Measures of body composition.

                                         FSHD          Range (FSHD)   Control       Range (control)   *p*-value
  -------------------------------------- ------------- -------------- ------------- ----------------- -----------
  **Measures of sarcopenia**                                                                          
  *ALM (kg)*                                                                                          
  Males and females combined             20.5 ± 4.4    15.3--27.5     26.5 ± 5.9    20.6--39.0        0.02
  Males                                  21.2 ± 4.7    15.3--27.5     27.7 ± 6.1    20.6--39.0        0.03
  Females                                17.7 ± 1.9    16.4--19.1     22.0 ± 1.1    21.1--22.8        0.15
  **Additional measures of lean mass**                                                                
  *Whole body lean mass (kg)*                                                                         
  Males and females combined             47.6 ± 6.0    40.5--57.3     56.6 ± 11.1   45.9--78.8        0.05
  Males                                  49.1 ± 5.8    40.5--55.0     58.8 ± 11.5   45.9--78.8        0.05
  Females                                41.7 ± 1.7    42.9--57.3     47.7 ± 0.6    47.2--48.1        0.10
  *Total arms lean mass (kg)*                                                                         
  Males and females combined             5.4 ± 1.1     43.9--73.9     7.5 ± 2.1     4.4--12.5         \< 0.01
  Males                                  5.7 ± 1.1     44.6--73.9     8.1 ± 2.1     5.1--12.5         0.01
  Females                                4.4 ± 0.04    43.9--44.5     5.5 ± 0.6     4.4--5.9          0.22
  *Total legs lean mass (kg)*                                                                         
  Males and females combined             15.1 ± 3.5    10.8--20.5     19.0 ± 3.9    14.0--26.5        0.03
  Males                                  15.5 ± 3.8    10.8--20.5     19.6 ± 4.2    14.0--16.5        0.06
  Females                                13.3 ± 2.0    11.9--14.7     16.4 ± 0.6    16.0--16.8        0.25
  **Additional measures of adiposity**                                                                
  *Whole body fat mass (kg)*                                                                          
  Males and females combined             33.7 ± 10.1   21.8--49.6     22.0 ± 6.9    11.2--49.6        \<0.01
  Males                                  33.5 ± 9.4    21.8--49.6     19.7 ± 5.3    11.2--49.6        \<0.01
  Females                                34.7 ± 17.0   22.7--46.7     31.1 ± 4.9    27.7--34.7        0.82
  *Total arms fat mass (kg)*                                                                          
  Males and females combined             3.2 ± 0.9     2.1--5.0       2.5 ± 0.9     1.4--4.9          0.09
  Males                                  3.1 ± 0.9     2.1--5.0       2.2 ± 0.5     1.4--4.9          0.02
  Females                                3.4 ± 1.2     2.5--4.3       3.8 ± 0.6     3.4--4.2          0.75
  *Total legs fat mass (kg)*                                                                          
  Males and females combined             10.7 ± 2.4    7.2--14.9      6.0 ± 1.6     3.1--12.1         \<0.01
  Males                                  10.3 ± 2.1    7.2--13.1      5.4 ± 1.1     3.1--12.1         \<0.01
  Females                                12.2 ± 3.9    9.4--14.9      8.5 ± 0.1     8.4--8.5          0.40

When males and females are combined, individuals with FSHD had lower appendicular lean mass (ALM), arm lean mass and leg lean mass but greater body and leg fat mass. When separated by sex, only males with FSHD exhibited a significant difference in these measures. kg: kilogram; data are presented in mean ± SD.

Measures of Sarcopenic Obesity {#S3.SS2}
------------------------------

Adults with FSHD were found to have an ALM that was 23% lower, as compared to the control group (*p* = 0.02, [Table 2](#T2){ref-type="table"}). This observation was further accompanied by an ALMI score that was 27% lower among individuals with FSHD, as compared to healthy controls (*p* \< 0.01, [Figure 1](#F1){ref-type="fig"}). Furthermore, % FM was 46% greater in FSHD, compared with controls (*p* \< 0.01, [Figure 2](#F2){ref-type="fig"}). Mean alterations in ALMI (6.3 ± 1.3 kg/m^2^) and % FM (40.0 ± 6.4%) among men with FSHD were sufficient to meet the diagnostic criteria for sarcopenic obesity; furthermore, six of eight men with FSHD were individually found to meet compositional requirements for the condition. Conversely, the same criteria were not met in female FSHD counterparts (ALMI: 6.2 ± 1.0 kg/m^2^, % FM: 44.1 ± 11.4%), and neither of the two FSHD females individually met the diagnostic requirements. Sarcopenic obesity was not observed in any of the control participants.

![Appendicular lean mass index (ALMI, kg/m^2^) in FSHD and controls. Individuals with FSHD had lower lean mass as compared to controls. Black circles indicate average data for each group. \**p* \< 0.01.](fphys-11-01008-g001){#F1}

![% fat mass in FSHD and controls. Individuals with FSHD had a higher % fat mass, as compared to controls. Black circles indicate average data for each group. \**p* \< 0.01.](fphys-11-01008-g002){#F2}

Additional Measures of Lean Mass {#S3.SS3}
--------------------------------

Additional measures of LM are located in [Table 2](#T2){ref-type="table"}. The absolute volume of whole body LM was 15% lower in FSHD, compared with controls, trending toward significance (*p* = 0.05). In addition, individuals with FSHD demonstrated a relative proportion of whole body LM to whole body total mass (% LM) that was 18% lower, compared with controls (*p* \< 0.01, [Figure 3](#F3){ref-type="fig"}). Furthermore, both the absolute volume of total arm (*p* \< 0.01) and total leg *(p* = 0.03) LM were lower in FSHD by 29 and 21%, respectively, as compared with controls.

![% lean mass in FSHD and controls. Individuals with FSHD had a lower % lean mass, as compared to controls. Black circles indicate average data for each group. \**p* \< 0.01.](fphys-11-01008-g003){#F3}

Additional Measures of Adiposity {#S3.SS4}
--------------------------------

Additional measures of adiposity are located in [Table 2](#T2){ref-type="table"}. Absolute volume of whole body FM was 53% greater in FSHD compared with controls (*p* \< 0.01). While the absolute volume of total leg FM among individuals with FSHD was 78% greater (*p* \< 0.01), the arms were somewhat less affected, with mean total arm FM only 28% greater in the FSHD group, which did not reach statistical significance (*p* = 0.09).

Self-Reported Measures of Functional Ability and Severity of Disease {#S3.SS5}
--------------------------------------------------------------------

Self-reported FSHD Health Index (HI) scores are located in [Table 3](#T3){ref-type="table"}, and range in value from 8.0 to 53.4 arbitrary units. Total FSHD-HI (*r* = −0.60), mobility and ambulation (*r* = −0.50), and activity limitation (*r* = −0.62) trended to be correlated with ALMI (*p* = 0.07), but not % FM or BMI (*p* \> 0.05 for all). Activity limitation also trended to be correlated with age (*r* = 0.62, *p* = 0.06). Other self-reported measures included an attenuated amount of physical activity completed each day among individuals with FSHD (activity metabolic index score; FSHD: 28.0 ± 33.6 kcal/day, control: 184.3 ± 152.7 kcal/day; *p* \< 0.01). Activity metabolic index score was not related to measures of body composition (% FM, ALMI) in either FSHD or control groups (*p* \> 0.05 for all).

###### 

FSHD Health Index (HI) Survey mean scores.

  FSHD health index category   Mean score (*n* = 10)
  ---------------------------- -----------------------
  Shoulder and arm function    53.4 ± 27.4
  Mobility and ambulation      48.3 ± 22.3
  Fatigue                      44.9 ± 15.9
  Social performance           44.0 ± 24.6
  Core strength and function   43.0 ± 19.8
  Activity limitation          40.1 ± 14.6
  Body image                   35.0 ± 22.1
  Social satisfaction          33.1 ± 22.8
  Emotional health             28.6 ± 18.5
  Pain                         19.9 ± 11.8
  Hand and finger function     19.7 ± 22.3
  Communication                19.5 ± 19.9
  Gastrointestinal function    10.3 ± 14.8
  Cognitive function           8.0 ± 12.8
  Total FSHD-HI Score          20.1 ± 8.8

Data are presented in mean ± SD.

Discussion {#S4}
==========

This study is the first to confirm the presence of sarcopenic obesity among individuals with FSHD, as reflected by a mean ALMI and % FM of \< 7.26 kg/m^2^ and \> 28% in afflicted males; furthermore, we are the first to show that individuals with FSHD exhibit the anatomic characteristics of sarcopenic obesity more often than age- and sex-matched controls. These observations are consistent with previous reports of significant alterations in body composition in people with FSHD, including widespread increases in measures of adiposity and reductions in lean mass ([@B33]; [@B29]; [@B20]).

Sarcopenic Obesity in Muscular Dystrophy {#S4.SS1}
----------------------------------------

Sarcopenic obesity is commonly found in other forms of muscular dystrophy, but has yet to be observed in FSHD. In fact, previous research has confirmed the presence of sarcopenic obesity among individuals with Bethlem myopathy, Ullrich congenital muscular dystrophy, rigid spine syndrome, limb girdle MD type 2d, Duchenne MD, and Becker MD ([@B27]; [@B26]; [@B32]). Consistent with our findings, alterations in body composition -- including greater FM and lower LM -- have been reported among individuals with FSHD ([@B33]). In fact, [@B33] noted a whole body LM value that was 17% lower in people with FSHD, as compared to control groups, a value which nearly mirrored our own observations (whole body lean mass 15% lower in FSHD group). Additionally, our findings of a % FM that was 53% greater among people with FSHD was similar to that reported by [@B33], in which whole body % FM was found to be 41% higher in the clinical group. Interestingly, despite observations of a higher volume of FM, these authors noted a BMI that was similar between groups ([@B33]), a finding that was consistent with our study. Also in line with our research, [@B33] reported significantly lower LM in the arms and legs. Similarly, observations of a greater volume of FM in the legs, but *not* in the arms, was also documented among people with FSHD. It is worthwhile to note that the DXA scanner utilized in the [@B33] study compartmentalized the limbs into upper and lower portions (arm, forearm, thigh, leg), while the device used in our research provided more generalized values (arms, legs). Therefore, drawing exact comparisons between appendicular measures of LM and FM between the two studies is not possible. Finally, as [@B33] did not assess ALM or ALMI in their study, we are not able to determine whether FSHD study participants met the diagnostic criteria for sarcopenic obesity, though as mean values of % FM in the FSHD group did not meet minimal threshold values (mean: 25.41 ± 8.33%) ([@B33]), the presence of the condition within this group of FSHD participants appears unlikely.

While the presence of sarcopenic obesity was only observed among male FSHD participants in our research, other studies have documented the condition among both sexes, in alternative forms of muscular dystrophy. In fact, in work by [@B27], in which 8 participants (male: 3, female: 5) with either Bethlem myopathy or Ullrich congenital muscular dystrophy were studied, sarcopenic obesity was confirmed in two of three males and all five females. Although the sample size was low in [@B27], they had three additional females, with all five meeting the criteria for sarcopenic obesity. Neither of our two females met the criteria which could indicate that the presence of sarcopenic obesity in different forms of muscular dystrophy is not equivocal. Notably, in adults without muscular dystrophy, it has been shown that females may be less, more, or as likely to develop sarcopenic obesity, as their male counterparts ([@B11]). Among whites, which formed the majority of our study (85%), rates of sarcopenic obesity are similar between age-matched males and females ([@B11]). However, sex-specific differences in FSHD phenotype presentation, in which females appear to be less affected than their male counterparts, have been reported ([@B41]; [@B36]). In our study, an elevated mean % FM of 44.1 ± 1.0% in the two females with FSHD did result in the fulfillment of one of the two objective requirements to meet the criteria for sarcopenic obesity (% FM: \> 40%). However, we also observed a mean ALMI of 6.2 ± 1.0 kg/m^2^ in the females with FSHD, a value that exceeds the minimum threshold associated with presentation of the condition (ALMI: \< 5.45 kg/m^2^). Therefore, although neither of the two females reached the diagnostic criteria for sarcopenic obesity, the small sample size in this study precludes any speculation regarding sex differences in sarcopenic obesity in adults with FSHD.

Clinical Relevance of Sarcopenic Obesity {#S4.SS2}
----------------------------------------

Identifying the presence of sarcopenic obesity in adults with FSHD is of high significance, as it may indicate an increased propensity toward greater impairments in functional capacity, and greater risk of morbidity and mortality. According to the Concord Health and Aging Project, sarcopenic obesity is linked to an increased risk of frailty and instrumental activity of daily living disability (IADL), a measure that is characterized by an inability to perform tasks for independent living ([@B19]). Furthermore, research by Baumgartner note that older men (\>60 years of age) with sarcopenic obesity are eight times more likely to develop three or more disabilities than age- and sex-matched controls ([@B3]). This observation is even more striking among older females with sarcopenic obesity, in which the risk for multiple disabilities was increased by a factor of 11 ([@B3]). In addition, the relationship between impaired physical function and sarcopenic obesity appears to be stronger than an association with either obesity or sarcopenia alone ([@B3]), thereby highlighting the cumulative effect of these factors on functionality in an aging population. Overall, these reports are in line with our own findings, in which a trending relationship between markers of sarcopenic obesity and self-reported impairments in mobility and ambulation or activity limitation was observed. While it is difficult to know whether sarcopenic obesity is more influential than FSHD when it comes to the etiology of physical impairment, these observations suggest that, at a minimum, it likely compounds the physical disability that individuals with FSHD already experience ([@B22]).

While DXA scanning is widely believed to be the gold-standard in body composition assessment, BMI charts are frequently used to estimate % FM in community settings and among older adults ([@B23]; [@B4]). However, the relationship between % FM and BMI is believed to be significantly influenced by age and sex, and may not be the best indicator of total body fatness ([@B12]). In our research, BMI was similar between FSHD and controls, but fat mass was significantly greater in people with FSHD. Furthermore, despite trending relationships between measures of sarcopenic obesity and physical function, an association between BMI and these same parameters was absent. Together, these findings cast doubt on the relevancy of using BMI as a valid tool for physical and functional assessment among people with FSHD. In final, DXA is a cost-effective and time efficient imaging modality that can be utilized as a measurement of disease severity and disease progression for future clinical trials.

Mechanisms Contributing to Sarcopenic Obesity {#S4.SS3}
---------------------------------------------

Though complex in nature, sarcopenic obesity is believed to be driven by a synergistic combination of biologic, hormonal, and behavioral influences. In fact, the atrophy and loss of type II muscle fibers -- a phenomenon that is believed to be predominantly responsible for the presentation of sarcopenia ([@B37]) -- is reportedly caused by an amalgamation of factors, including neurodegenerative processes within spinal α-motor neurons, dysregulation of anabolic hormone production (insulin, growth, and sex hormones), and inadequate nutritional intake ([@B37]). Furthermore, sarcopenia is believed to be mediated by a deconditioned state ([@B37]), and the presence of a significantly reduced physical activity score in the FSHD cohort in our study suggests that deconditioning may have been a precipitating factor in the manifestation of sarcopenia. It is worthwhile to note that while individuals with FSHD have been reported to exhibit reductions in both type IIa and IIx muscle fibers ([@B7]), it is unclear whether this phenomenon is caused by the factors described above, or is purely an intrinsic result of the disease itself. As such, individuals with FSHD exhibit indirect evidence of DUX4 protein expression in muscle biopsies ([@B40]), which leads to an inability to properly replace diseased or damaged muscle tissue with new myofibers ([@B6]) which may lead to a pro-adipogenic state within muscle of adults with FSHD. In addition, physical inactivity has been widely cited as a contributor in the development of obesity ([@B28]). Observations of physical inactivity have been noted in other forms of muscular dystrophy, whereby 44% of people with limb-girdle or Charcot-Marie-Tooth muscular dystrophy exhibit an inability to meet minimum threshold recommendations for daily exercise ([@B1]). Thus, the physical *inactivity* demonstrated in our FSHD cohort likely not only contributed to sarcopenia, but also obesity. The lack of a correlation between either physical activity and % FM (*p* = 0.79) or physical activity and ALMI (*p* = 0.15), among people with FSHD, however, suggests that the inherent influence of FSHD likely plays a significant role in the etiology of sarcopenic obesity.

Limitations {#S4.SS4}
-----------

Limitations of this study should be considered when interpreting the data. The small sample size in female participants, likely contributed to an inability for the females on average to meet the diagnostic criteria for sarcopenic obesity. Previous research by [@B27] has confirmed the presence of sarcopenic obesity in both male and female dystrophic groups, but not specifically in FSHD. Furthermore, as we did not control for clinical severity within the FSHD group, it is possible that our female FSHD participants exhibited a lesser-degree of disease than their male counterparts, whereby the presence of anatomic alterations in body composition were not yet manifest, a theory which has been supported by previous research ([@B41]; [@B36]). Since our study used a DXA scan and not MRI imaging to assess body composition, we were unable to assess whether differences in % FM between FSHD and control groups were driven by general increases in adiposity, or by intramuscular fat infiltration, a finding which has been previously reported ([@B20]), and which is believed to be a hallmark characteristic of FSHD. Finally, while all FSHD study members were Caucasian, 3 of 10 control participants (all men) were of differing races, a factor that may have a confounding effect on study outcomes. Though alterations in body composition between races have been widely reported ([@B18]), it appears that these differences may be driven by sex, whereby variances are noted primarily among female racial groups ([@B15]). According to research by [@B13], measures of total body fat and fat-free mass are similar between Black and White males, though whether the same is true between White and Hispanic or Asian males remains to be elucidated. Finally, because of the case-control study design, we are unable to establish a causative relationship between FSHD and presence of sarcopenic obesity.

Conclusion {#S5}
==========

This research is the first to show that men with FSHD meet the diagnostic criteria for sarcopenic obesity more often than age-matched controls. Sarcopenic obesity is a complex medical condition, which manifests as a number of both acute and long-term implications. Identifying individuals that may be at an increased risk for sarcopenic obesity, will lead to preventative rehabilitative strategies to reduce the prevalence of the condition, among individuals of all ages and health statuses. Furthermore, by identifying sarcopenic obesity as a comorbidity of FSHD, we have taken a major step forward in understanding the anatomic and physiologic contributions to impaired health and physical function in this genetic disease. Future research in this area should focus on strategies (i.e., exercise) to address the sarcopenic obesity-driven losses in functionality, and improve quality of life among individuals with neuromuscular impairment.
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